Akero Therapeutics, Inc.
NASDAQ:AKRO
28.25 (USD) • At close December 27, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Akero Therapeutics, Inc. |
Symbool | AKRO |
Munteenheid | USD |
Prijs | 28.25 |
Beurswaarde | 1,971,824,575 |
Dividendpercentage | 0% |
52-weken bereik | 15.32 - 37 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Andrew Cheng M.D., Ph.D. |
Website | https://www.akerotx.com |
An error occurred while fetching data.
Over Akero Therapeutics, Inc.
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates,
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)